Latest News

  • 29.01.2013
    XTL BIOPHARMACEUTICALS FILES AN URGENT REQUEST WITH THE DISTRICT COURT OF TEL AVIV-JAFFA FOR SETTLEMENT IN ORDER TO EXTEND THE EXERCISE PERIOD OF WARRANTS (SERIES 2) TO DECEMBER 31, 2013
  • 29.01.2013
    XTL BIOPHARMACEUTICALS FILES AN URGENT REQUEST WITH THE DISTRICT COURT OF TEL AVIV-JAFFA FOR SETTLEMENT IN ORDER TO EXTEND THE EXERCISE PERIOD OF WARRANTS (SERIES 2) TO DECEMBER 31, 2013
  • 30.01.2013
    XTL BIOPHARMACEUTICALS FILES AN URGENT REQUEST WITH THE DISTRICT COURT OF TEL AVIV-JAFFA FOR A TEMPORARY ORDER TO EXTEND THE EXERCISE PERIOD OF WARRANTS (SERIES 2) TO APRIL 30, 2013 IN ORDER TO PROVIDE SUFFICIENT TIME TO COMPLETE THE NECESSARY PROCEDURES
  • 30.01.2013
    THE DISTRICT COURT OF TEL AVIV-JAFFA APPROVED THE CONVENING AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS AND WARRANT HOLDERS
  • 03.02.2013
    XTL BIOPHARMACEUTICALS CONVENES GENERAL MEETING OF SHAREHOLDERS AND WARRANT (SERIES 2) HOLDERS
  • 06.02.2013
    XTL BIOPHARMACEUTICALS ANNOUNCES THE APPROVAL OF THE TEMPORARY ORDER BY THE DISTRICT COURT OF TEL AVIV-JAFFA TO EXTEND THE EXERCISE PERIOD OF WARRANTS (SERIES 2) TO APRIL 30, 2013
  • 21.02.2013
    XTL BIOPHARMACEUTICALS FILES A REQUEST WITH THE DISTRICT COURT OF TEL AVIV-JAFFA FOR APPROVAL OF THE SETTLEMENT AND THE EXTENSION OF THE WARRANTS (SERIES 2) TO DECEMBER 31, 2013
  • 21.02.2013
    XTL BIOPHARMACEUTICALS ANNOUNCES RESULTS OF ITS EXTRAORDINARY GENERAL MEETING OF WARRANT (SERIES 2) HOLDERS
  • 21.02.2013
    XTL BIOPHARMACEUTICALS ANNOUNCES RESULTS OF ITS EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
  • 06.03.2013
    XTL BIOPHARMACEUTICALS AND KITOV MUTUALLY AGRRED TO CEASE NEGOTIATIONS
  • 12.03.2013
    XTL BIOPHARMACEUTICALS ANNOUNCES THE APPROVAL OF THE SETTLEMENT AND THE EXTENSION OF THE WARRANTS (SERIES 2) TO DECEMBER 31, 2013 THE DISTRICT COURT OF TEL AVIV-JAFFA
  • 24.03.2013
    XTL BIOPHARMACEUTICALS PRESENTS ITS FINANCIAL STATEMENTS FOR THE YEAR ENDED ON DECEMBER 31, 2012
  • 08.05.2013
    XTL BIOPHARMACEUTICALS CONVENES AN ANNUAL GENERAL MEETING
  • 30.05.2013
    XTL BIOPHARMACEUTICALS LTD. PRESENTS ITS INTERIM FINANCIAL STATEMENTS AS OF MARCH 31, 2013
  • 12.06.2013
    XTL BIOPHARMACEUTICALS LTD. PRESENTS ITS INTERIM FINANCIAL STATEMENTS AS OF MARCH 31, 2013
  • 25.06.2013
    XTL BIOPHARMACEUTICALS ANNOUNCES THE EXTENSION OF LOCK-UP AGREEMENT WITH FORMER XTEPO SHAREHOLDERS
  • 25.06.2013
    XTL BIOPHARMACEUTICALS ANNOUNCES THE POSTPONEMENT OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
  • 25.06.2013
    #2 - XTL BIOPHARMACEUTICALS ACQUIRES STAKE IN PROTEOLOGICS LTD.
  • 25.06.2013
    XTL BIOPHARMACEUTICALS ANNOUNCES THE POSTPONEMENT OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
  • 25.06.2013
    INVESTORS EXERCISE WARRANTS TOTALING NIS 4.2 MILLION AT NIS 1.05 PER SHARE
  • 25.06.2013
    XTL BIOPHARMACEUTICALS ANNOUNCES STRATEGIC COLLABORATION FRAMEWORK AGREEMENT WITH CLALIT HEALTH SERVICES – CLALIT RESEARCH INSTITUTE LTD. AND MOR RESEARCH APPLICATIONS LTD.
  • 13.02.2012
    XTL BIOPHARMACEUTICALS CONVENES AN ANNUAL GENERAL MEETING
  • 06.03.2012
    XTL BIOPHARMACEUTICALS LTD. APPLIES TO LIST ITS ADRS ON NASDAQ
  • 18.03.2012
    XTL BIOPHARMACEUTICALS SUCCESSFULLY COMPLETES A CAPITAL RAISE OF APPROXIMATELY NIS 9.1 MILLION LED BY INSTITUTIONAL INVESTORS
  • 19.03.2012
    XTL BIOPHARMACEUTICALS ANNOUNCES RESULTS OF ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS
  • 29.03.2012
    XTL BIOPHARMACEUTICALS PRESENTS ITS FINANCIAL STATEMENTS FOR THE YEAR ENDED ON DECEMBER 31, 2011
  • 15.04.2012
    XTL BIOPHARMACEUTICALS LTD. SIGNS LETTER OF INTENT TO ACQUIRE A COMPANY
  • 15.04.2012
    XTL BIOPHARMACEUTICALS LTD. CONVENES AN EXTRAORDINARY GENERAL MEETING
  • 15.04.2012
    XTL BIOPHARMACEUTICALS LTD. NAMES DR. BEN-ZION WEINER TO ITS BOARD OF DIRECTORS
  • 09.05.2012
    XTL BIOPHARMACEUTICALS PRESENTS ITS INTERIM FINANCIAL STATEMENTS AS OF MARCH 31, 2012
  • 29.05.2012
    XTL BIOPHARMACEUTICALS ANNOUNCES RESULTS OF ITS EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
  • 10.06.2012
    XTL BIOPHARMACEUTICALS LTD. JOINS "TA BLUETECH-50" INDEX
  • 10.06.2012
    XTL BIOPHARMACEUTICALS LTD. JOINS "TA MIDCAP-50" INDEX
  • 14.06.2012
    XTL BIOPHARMACEUTICALS LTD. ANNOUNCES AGREEMENT FOR THE ACQUISITION OF CONTROL OVER INTERCURE
  • 19.06.2012
    XTL BIOPHARMACEUTICALS LTD. ANNOUNCES ACQUISITION OF KITOV PHARMACEUTICALS LTD.
  • 09.07.2012
    XTL BIOPHARMACEUTICALS LTD. ALLOCATES 7,165,662 SHARES TO INTERCURE LTD.
  • 23.08.2012
    XTL BIOPHARMACEUTICALS LTD. ANNOUNCES TERMINATION OF THE AGREEMENT WITH PRESIDIO PHARMACEUTICALS INC.
  • 30.08.2012
    XTL BIOPHARMACEUTICALS LTD. PRESENTS ITS INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2012
  • 10.09.2012
    XTL BIOPHARMACEUTICALS LTD. ANNOUNCES PROGRESS IN THE ACQUISITION OF KITOV PHARMACEUTICALS LTD
  • 24.09.2012
    XTL BIOPHARMACEUTICALS – INTERCURE SIGNS A STRATEGIC SERVICE AGREEMENT
  • 24.09.2012
    XTL BIOPHARMACEUTICALS PROVIDES FAVORABLE UPDATE ON NASDAQ LISTING PROCESS
  • 21.11.2012
    #1 - XTL BIOPHARMACEUTICALS ACQUIRES STAKE IN PROTEOLOGICS LTD.
  • 25.11.2012
    XTL BIOPHARMACEUTICALS LTD. PRESENTS ITS INTERIM FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2012
  • 27.11.2012
    XTL BIOPHARMACEUTICALS POSTPONES EGM TO DECEMBER 6, 2012
  • 28.11.2012
    XTL BIOPHARMACEUTICALS PROVIDES UPDATED EXTRAORDINARY GENERAL SHAREHOLDER MEETING CONVENING LETTER
  • 13.12.2012
    XTL BIOPHARMACEUTICALS ANNOUNCES CHANGES IN NEGOTIATIONS WITH KITOV. EXTRAORDINARY GENERAL MEETING ADJOURNED WITHOUT VOTING
  • 27.02.2011
    XTL BIOPHARMACEUTICALS PRESENTS ITS PROSPECTUS TO THE ISRAELI SECURITIES AUTHORITY
  • 07.03.2011
    XTL BIOPHARMACEUTICALS ANNOUNCES THE RESULTS OF THE OFFERING ON THE TEL-AVIV STOCK EXCHANGE OF ITS ORDINARY SHARES AND WARRANTS TO PURCHASE ITS ORDINARY SHARES
  • 24.03.2011
    XTL BIOPHARMACEUTICALS ANNOUNCES ENTERING INTO A TERM SHEET BY WHICH IT WILL ACQUIRE THE ACTIVITY OF MINOGUARD LTD
  • 29.03.2011
    XTL BIOPHARMACEUTICALS PRESENTS ITS FINANCIAL STATEMENTS FOR THE YEAR ENDED ON DECEMBER 31, 2010
  • 21.04.2011
    XTL BIOPHARMACEUTICALS LTD ANNOUNCES IT SUBMITTED AN APPLICATION TO THE FOOD AND DRUG ADMINISTRATION (FDA) REQUESTING THAT ITS EPO DRUG BE GRANTED ORPHAN DRUG STATUS
  • 29.05.2011
    XTL BIOPHARMACEUTICALS ANNOUNCES RECEIPT OF ORPHAN-DRUG DESIGNATION IN THE UNITED STATES FOR THE COMPANY'S DRUG TREATMENT FOR MULTIPLE MYELOMA
  • 30.05.2011
    XTL BIOPHARMACEUTICALS PRESENTS ITS INTERIM FINANCIAL STATEMENTS AS OF MARCH 31, 2011
  • 01.06.2011
    XTL BIOPHARMACEUTICALS CONVENES AN ANNUAL GENERAL MEETING
  • 12.07.2011
    XTL BIOPHARMACEUTICALS ANNOUNCES RESULTS OF ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS
  • 29.08.2011
    XTL BIOPHARMACEUTICALS PRESENTS ITS INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2011
  • 29.08.2011
    XTL BIOPHARMACEUTICALS ANNOUNCES PROTEINS RESEARCH FOR THE COMPANY'S DRUG TREATMENT FOR MULTIPLE MYELOMA
  • 03.11.2011
    XTL BIOPHARMACEUTICALS TO ACQUIRE NICURE
  • 24.11.2011
    XTL BIOPHARMACEUTICALS PRESENTS ITS INTERIM FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2011
  • 30.11.2011
    XTL BIOPHARMACEUTICALS ANNOUNCES THE COMPLETION OF MINOGUARD'S ACTIVITY ACQUISITION
  • 03.01.2010
    XTL BIOPHARMACEUTICALS ANNOUNCES AN AMENDMENT OF THE AGREEMENT FOR THE ACQUISITION OF THE USE PATENT ON RECOMBINANT ERYTHROPOIETIN (rHuEPO) FOR THE TREATMENT OF MULTIPLE MYELOMA
  • 15.01.2010
    XTL BIOPHARMACEUTICALS PUBLISHED AN IMMEDIATE REPORT REGARDING AN EXTRAORDINARY PRIVATE PLACEMENT
  • 15.01.2010
    XTL BIOPHARMACEUTICALS CONVENES AN EXTRAORDINARY SHAREHOLDER MEETING FOR THE APPROVAL OF THE XTL – BIO-GAL AGREEMENT (VIA XTEPO LTD.) AND SHARE ALLOCATION
  • 19.01.2010
    XTL BIOPHARMACEUTICALS CONVENES AN ANNUAL SHAREHOLDER MEETING
  • 02.03.2010
    XTL BIOPHARMACEUTICALS ANNOUNCES THE RESULTS OF ITS EXTRAORDINARY GENERAL MEETING
  • 02.03.2010
    XTL BIOPHARMACEUTICALS ANNOUNCES THE RESULTS OF ITS ANNUAL GENERAL MEETING
  • 24.03.2010
    XTL BIOPHARMACEUTICALS PRESENTS ITS FINANCIAL STATEMENTS FOR THE YEAR ENDED ON DECEMBER 31, 2009
  • 26.04.2010
    XTL BIOPHARMACEUTICALS EXTENDS THE COMPLETION DATE FOR THE BIO-GAL TRANSACTION
  • 30.05.2010
    XTL BIOPHARMACEUTICALS PRESENTS ITS INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED ON MARCH 31, 2010
  • 04.08.2010
    XTL BIOPHARMACEUTICALS ANNOUNCES COMPLETION OF THE BIO-GAL TRANSACTION
  • 27.08.2010
    XTL BIOPHARMACEUTICALS PRESENTS ITS INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2010
  • 26.09.2010
    XTL BIOPHARMACEUTICALS ANNOUNCES CANADIAN PATENT OFFICE APPROVAL
  • 25.11.2010
    XTL BIOPHARMACEUTICALS PRESENTS ITS INTERIM FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2010
  • 01.12.2010
    XTL BIOPHARMACEUTICALS LTD ANNOUNCES SUBMISSION OF DRAFT SHELF PROSPECTUS TO THE ISRAEL SECURITIES AUTHORITY
  • 27.01.2014
    XTL In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus